AL 102
Alternative Names: AL-102; BMS 986115; WHG-626Latest Information Update: 28 May 2024
At a glance
- Originator Bristol-Myers Squibb
- Developer Ayala Pharmaceuticals; Bristol-Myers Squibb; Novartis
- Class Amides; Antineoplastics; Benzene derivatives; Benzodiazepines; Fluorinated hydrocarbons; Small molecules
- Mechanism of Action Amyloid precursor protein secretase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Fibroma
- No development reported Haematological malignancies; Multiple myeloma; Solid tumours
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in Unknown (PO)
- 28 Mar 2024 Ayala Pharmaceuticals announces intention to submit an NDA application for AL 102
- 26 Mar 2024 Immunome acquires AL 102 from Ayala Pharmaceuticals